The aging population with schizophrenia may still experience symptoms as they age in addition to the increased risk for psychosis they have due to age-related deterioration of cortical areas and neurochemical changes, comorbid physical illnesses, social isolation, sensory deficits, and polypharmacy.  This webinar will evaluate current literature to review the current utilization of long-acting injectable antipsychotic medications in this population.  Review and management of potential adverse effects in the aging population who utilize long-acting injectable antipsychotic medications will be presented.  Clinical pearls on the development of an administration and treatment plan for long-acting injectable antipsychotic medications use in an aging population will be reviewed for incorporation in practice.